EGFR and neoplasm: Specifically, inhibition of the JAK-STAT pathway could underlie the observed high infection rates by impairing immune surveillance (61); broad modulation of EGFR signaling, potentially via aberrant MAPK pathway activation, might contribute to reported tumor risks (62); and vascular endothelial dysfunction emerges as a candidate mechanism for thromboembolic events (63).